Biomonitoring of Enniatin B1 and Its Phase I Metabolites in Human Urine: First Large-Scale Study

• Main Authors: Yelko Rodríguez-Carrasco, Alfonso Narváez, Luana Izzo, Anna Gaspari, Giulia Graziani, Alberto Ritieni
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Toxins
• Subjects: Enniatin B1; biomonitoring; in vivo; metabolomics; high resolution mass spectrometry (HRMS)
• Online Access: https://www.mdpi.com/2072-6651/12/6/415

Enniatins (Enns) are mycotoxins produced by <i>Fusarium</i> spp. which are a fungus widely spread throughout cereals and cereal-based products. Among all the identified enniatins, Enn B1 stands as one of the most prevalent analogues in cereals in Europe. Hence, the aim of this study was to evaluate for the first time the presence of Enn B1 and its phase I metabolites in 300 human urine samples using an ultrahigh-performance liquid chromatography high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) methodology. Enn B1 was detected in 94.3% of samples ranging from 0.007 to 0.429 ng/mL (mean value: 0.065 ng/mL). In accordance with previous in vitro and in vivo analysis, hydroxylated metabolites (78.0% samples) and carbonylated metabolites (66.0% samples) were tentatively identified as the major products. Results from this biomonitoring study point to a frequent intake of Enn B1 in the studied population, suggesting that in-depth toxicological studies are needed in order to understand the potential effects in humans.